【大行评级|大摩:上调金斯瑞生物科技目标价至21.9港元 重申“增持”评级】摩根士丹利发表研报指,展望2025年,金斯瑞生物科技复苏趋势有望持续,经营前景变得更为乐观。全球本地化发展战略的推动、CRO和CDMO订单增加,以及百斯杰业务取得积极进展,相信为未来可持续扩张铺路。该行重申对其“增持”评级,目标价从18.6港元上调至21.9港元。

金融界
17 Mar
摩根士丹利发表研报指,展望2025年,金斯瑞生物科技复苏趋势有望持续,经营前景变得更为乐观。全球本地化发展战略的推动、CRO和CDMO订单增加,以及百斯杰业务取得积极进展,相信为未来可持续扩张铺路。该行重申对其“增持”评级,目标价从18.6港元上调至21.9港元。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10